Are you someone who has had diabetes for several years and you simply can't control your sugar anymore on oral medicines? Diabetes is a progressive disease and sometimes adjustments in medicine regimens need to be made to help control blood sugar.
What Is Bydureon?
Bydureon, is a long-acting form of the medication Byetta that is given once per week. Bydureon is a GLP-1 (glucagon-like peptide 1) agonist that stimulates insulin secretion when it comes into contact with glucose.
It has also been shown to preserve beta cell function (beta cells make insulin) and has been proven to promote weight loss by delaying gastric emptying and increasing feelings of fullness. Studies have shown that people taking Bydureon lose an average of about five pounds by month six of taking the medication and have been shown to keep it off by year three. Learn more about bydureon insulin pen.
Blood Sugar Control:
While clinical trials have shown that treatment with Bydureon can help to reduce A1c by about 1.5 percent, Bydureon is not used as a first-line diabetes treatment. Instead, it is typically used as a second or third agent in combination with metformin or a sulfonylurea.
Previously, Bydureon was only available using a syringe that was rather long and thick. Although the injection was only once per week, some people complained of discomfort. However, now Bydureon is available for use via pen. The pen is likely to be more comfortable and easier to use than the syringe.
Who Is a Candidate for Bydureon?
Discuss with your healthcare provider if you are a candidate for Bydureon. Bydureon is not meant to be used as a weight loss drug and is typically used in conjunction with other diabetes medicines. If you are someone with type 2 diabetes whose blood sugars are not at goal and can afford to lose some weight than Bydureon might be an option for you. Visit this website to get more info about ultimate guide to Bydureon pen.
Who Should Not Take Bydureon?
In animal studies, Bydureon caused rats to develop tumors of the thyroid gland. Therefore, Bydureon is contraindicated in patients with a personal or family history of medullary thyroid cancer (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). People with sensitivity to exenatide or to any product components should also not take Bydureon.
Because Bydureon delays gastric emptying, the most common side effects include nausea and vomiting. Nausea commonly happens when first starting the medication and decreases over time when the body gets used the medication. Other side effects include headaches, diarrhea, redness at the injection site.